Institution
Hull and East Yorkshire Hospitals NHS Trust
Healthcare•Hull, United Kingdom•
About: Hull and East Yorkshire Hospitals NHS Trust is a healthcare organization based out in Hull, United Kingdom. It is known for research contribution in the topics: Population & Randomized controlled trial. The organization has 757 authors who have published 636 publications receiving 13486 citations.
Papers published on a yearly basis
Papers
More filters
••
University of Warwick1, University Hospitals Birmingham NHS Foundation Trust2, University of Salford3, Cardiff University4, Institute of Cancer Research5, Beatson West of Scotland Cancer Centre6, Leeds Teaching Hospitals NHS Trust7, Weston Park Hospital8, Maidstone Hospital9, Royal Bournemouth Hospital10, Derby Hospitals NHS Foundation Trust11, Guy's Hospital12, Cheltenham General Hospital13, Queen Alexandra Hospital14, The Queen's Medical Center15, Musgrove Park Hospital16, Hull and East Yorkshire Hospitals NHS Trust17, Mount Vernon Hospital18, Royal Surrey County Hospital19, East Sussex County Council20, Western General Hospital21, Queen's University Belfast22, East Lancashire Hospitals NHS Trust23, Churchill Hospital24, Telford25, Royal Devon and Exeter Hospital26, Nottingham University Hospitals NHS Trust27, Clatterbridge Cancer Centre NHS Foundation Trust28, Swansea University29
TL;DR: Zoledronic acid showed no evidence of survival improvement and should not be part of standard of care for this population of men, and heterogeneity in treatment effect across prespecified subsets was not found.
1,502 citations
••
Malmö University1, Imperial College London2, French Institute of Health and Medical Research3, Leiden University Medical Center4, Technische Universität München5, University of Amsterdam6, Hull and East Yorkshire Hospitals NHS Trust7, International Atomic Energy Agency8, University of Würzburg9, Lund University10, Aberdeen Royal Infirmary11, Mayo Clinic12, University College London13
TL;DR: The European procedural guidelines for radionuclide imaging of myocardial perfusion and viability are presented in 13 sections covering patient information, radiopharmaceuticals, injected activities and dosimetry, stress tests, imaging protocols and acquisition, quality control and reconstruction methods, and positron emission tomography.
Abstract: The European procedural guidelines for radionuclide imaging of myocardial perfusion and viability are presented in 13 sections covering patient information, radiopharmaceuticals, injected activities and dosimetry, stress tests, imaging protocols and acquisition, quality control and reconstruction methods, gated studies and attenuation-scatter compensation, data analysis, reports and image display, and positron emission tomography. If the specific recommendations given could not be based on evidence from original, scientific studies, we tried to express this state-of-art. The guidelines are designed to assist in the practice of performing, interpreting and reporting myocardial perfusion SPET. The guidelines do not discuss clinical indications, benefits or drawbacks of radionuclide myocardial imaging compared to non-nuclear techniques, nor do they cover cost benefit or cost effectiveness.
493 citations
••
Nicholas A. Kennedy1, Nicholas A. Kennedy2, Nicholas A. Kennedy3, Graham A. Heap2 +157 more•Institutions (15)
TL;DR: Clinical and pharmacokinetic factors that predict primary non-response at week 14 after starting treatment, non-remission at week 54, and adverse events leading to drug withdrawal are identified.
369 citations
••
University of Warwick1, University College London2, The Royal Marsden NHS Foundation Trust3, Queen Alexandra Hospital4, Hull and East Yorkshire Hospitals NHS Trust5, Mount Vernon Hospital6, Beatson West of Scotland Cancer Centre7, Royal Surrey County Hospital8, Cardiff University9, Western General Hospital10, University of Glasgow11
TL;DR: Survival remains disappointing in men presenting with M1 disease who are started on only long-term androgen deprivation therapy (ADT), despite active treatments being available at first failure of ADT.
356 citations
••
TL;DR: There is stronger evidence, however, that measurement of PCT has a role in reducing the antibiotic exposure of critical care patients and the cost-effectiveness of this is likely to depend on the pre-implementation length of an average antibiotic course and the subsequent impact of implementation on emerging antibiotic resistance.
Abstract: Sepsis is a leading cause of mortality in critically ill patients. Delay in diagnosis and initiation of antibiotics have been shown to increase mortality in this cohort. However, differentiating sepsis from non-infectious triggers of the systemic inflammatory response syndrome (SIRS) is difficult, especially in critically ill patients who may have SIRS for other reasons. It is this conundrum that predominantly drives broad-spectrum antimicrobial use and the associated evolution of antibiotic resistance in critical care environments. It is perhaps unsurprising, therefore, that the search for a highly accurate biomarker of sepsis has become one of the holy grails of medicine. Procalcitonin (PCT) has emerged as the most studied and promising sepsis biomarker. For diagnostic and prognostic purposes in critical care, PCT is an advance on C-reactive protein and other traditional markers of sepsis, but is not accurate enough for clinicians to dispense with clinical judgement. There is stronger evidence, however, that measurement of PCT has a role in reducing the antibiotic exposure of critical care patients. For units intending to incorporate PCT assays into routine clinical practice, the cost-effectiveness of this is likely to depend on the pre-implementation length of an average antibiotic course and the subsequent impact of implementation on emerging antibiotic resistance. In most of the trials to date, the average baseline duration of the antibiotic course was longer than is currently standard practice in many UK critical care units. Many other biomarkers are currently being investigated. To be highly useful in clinical practice, it may be necessary to combine these with other novel biomarkers and/or traditional markers of sepsis.
310 citations
Authors
Showing all 760 results
Name | H-index | Papers | Citations |
---|---|---|---|
George Davey Smith | 224 | 2540 | 248373 |
John J.V. McMurray | 178 | 1389 | 184502 |
John G.F. Cleland | 137 | 1172 | 110227 |
David A. Jackson | 136 | 1095 | 68352 |
Ian Ford | 134 | 678 | 85769 |
Richard C. Trembath | 107 | 368 | 41128 |
David J. Torgerson | 83 | 537 | 27275 |
David C. Wheeler | 77 | 328 | 25238 |
Andrew Yule Finlay | 71 | 344 | 24111 |
Richard A. Brown | 67 | 287 | 16860 |
Andrew L. Clark | 65 | 426 | 15108 |
Philip A. Kalra | 49 | 315 | 8566 |
Ken Farrington | 49 | 290 | 8565 |
Charles R.V. Tomson | 47 | 267 | 9937 |
Eric S. Kilpatrick | 42 | 132 | 6417 |